Bio Preventive Medicine Corp. (hereinafter referred to as "BPM", TW stock code: 6810) announced that it has completed the signing of a License MOU with South Korea's Boditech Med Inc. (Boditech Med) to authorize the Korean partners to integrate DNlite-IVD103 into its POCT (Point of Care Testing) products, targeting disease management and remote care business opportunities for the more than 500 million people with diabetes worldwide.
According to the MOU, Boditech Med will obtain the global non-exclusive authorization use of B.jpg)
PM’s DNlite-IVD103 on two POCT platforms. On countries and regions of authorization, the amount of the license fee, and the amount and method of future royalty payment, the two parties will further discuss the details and sign a formal contract.
BPM stated that Boditech Med is listed on the Korean Exchange. It is an IVD company that develops both reagents and its own analytical instruments. Its products include diagnostic reagents, automated immunoassay analyzers, etc., and are marketed in more than 120 countries around the world. With cumulative sales of more than 120,000 units of its own brand fluorescence immunoassay analyzers, it has rich operational experience and a solid sales network. The company's revenue and profits have grown steadily in recent years, and it ranks among the leaders in the industry.
DNlite-IVD103 is the world's first testing reagent for precise management and prevention of rapid deterioration of renal function in diabetic nephropathy (DKD). By detecting changes in specific biomarkers in urine, it can effectively predict the deterioration of renal function in the next 5 years for patients who require precise care and management of the di(1).jpg)
sease.
BPM President, Dr. Karen Tseng, indicates that BPM possesses the unique antibody raw material, key technologies, and global patent protection. DNlite-IVD103 has entered the POCT market through this licensing process and BPM has initiated its first international licensing agreement. The innovative technology and R&D capabilities at BPM are internationally valued and recognized. The company is open to commercial licensing of DNlite-IVD103, and will adopt both strategies, own brand product promotion and technology licensing, to accelerate the wide usage of DNlite-IVD103 and pursue long-term and stable business development for the company.
About Boditech Med:
Boditech Med is a global leader in next-generation on-site diagnostics with decades of success in improving health and quality of life through innovative in vitro diagnostic solutions. Since its establishment in 1998, the company has developed 93 biomarkers supporting capillary, venous blood, and plasma tests, assisting patients and clinicians in 120 countries.